INDUSTRY NEWS
GLOBAL INDUSTRY INSIGHTS A roundup of world news in the science industry
PISTOIA FORGES AHEAD WITH CARBON FOOTPRINT MEASUREMENT
TRUMP REVOKES BIOTECHNOLOGY ORDER
President Trump has revoked former President Biden’s September 2022 EO 14081 order, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy”. The current president has said it: “funnelled Federal resources into radical biotech and biomanufacturing initiatives under the guise of environmental policy.” The original initiative offered concrete plans to accelerate biotechnology innovation and grow the US bioeconomy across sectors including health, agriculture, and energy with a view to maintaining competitiveness in the global bioeconomy. It also pledged to collect genomic and multiomic information to “drive advances in health, climate, energy, food, agriculture and bioeconomy-related research and development as well as to “set forth a plan to fill any data gaps and make new and existing public data findable, accessible, interoperable, and reusable in ways that are standardised, secure, and transparent.” Commentators have said that revoking this order is likely to alter the public health data landscape considerably.
6
www.scientistlive.com
Global not-for-profit organisation, The Pistoia Alliance, is launching the next phase of its project to measure and reduce the carbon footprint of clinical trials. The initiative will assess the environmental impact of digital trial delivery methods (eConsent, decentralised clinical trials (DCT)) and digital health solutions (devices and applications), compared with traditional, paper-based approaches. By closing a critical gap in the understanding of whether digital technologies are more sustainable, the project will establish a standardised methodology for evaluating the use of digital tools in clinical trials. To further support this effort, the Alliance is also launching a new whitepaper that explores the broader sustainability challenges in pharmaceutical R&D and the need for better measurement frameworks to drive meaningful change.
“The life-sciences industry
is under increasing pressure to reduce its environmental impact, and clinical trials are a significant contributor. As CROs and sponsors embrace digital technologies, it is critical to understand whether these innovations are genuinely more sustainable than traditional methods,” explains Thierry Escudier, portfolio lead at the Pistoia Alliance. The healthcare sector contributes
approximately 5% of global greenhouse gas emissions and clinical trials are a significant part of this, producing approximately 100 million tonnes of carbon dioxide, equivalent to the annual carbon footprint of Belgium. These emissions stem from all activities performed to run clinical trials at pharmaceutical companies’ facilities and hospital sites.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
